It was estimated that small cell lung cancer (SCLC) accounts for about one Sixth of all lung
cancer cases. Patients with SCLC are usually diagnosed in advanced stage of disease. Unfortunately
at this stage, prognosis is very poor. Bevacizumab is a monoclonal antibody against VEGF, which
inhibits the angiogenesis in malignant tumors. Although Bevacizumab has been approved for firstline
use in advanced non-SCLC, the first report has been available for its use in SCLC. In this review,
we summarized all available data on the use of Bev in SCLC patients. Finally, future directions are discussed.
Keywords: Bevacizumab, lung cancer, maintenance, small cell.
Rights & PermissionsPrintExport